CLDN1 and skin infection: Thus, the aim of the study is the evaluation of a wall fragment derived from a patented strain of C. acnes DSM28251 (donated by Aileens Pharma Srl) alone and conjugated to a mucopolysaccharide carrier (HAc40) in counteracting S. aureus pathogenic action on two tight junction proteins (Claudin-1 and ZO-1) in an ex vivo porcine skin infection model used as in vivo alternative for medical devices testing, drug skin permeation, and cosmetics studies [44].